Start-up Workshop Panel
Rami Hannoush
General Partner and Chief Scientific Officer, Mubadala Capital
Our company focuses on early-stage investments in life sciences and healthcare.
Dr. Hannoush is currently Chief Scientific Officer at a biotech stealth company, and a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. He co-heads the healthcare investment platform and oversees its strategy, and also leads the firm’s efforts in life sciences company creation. Rami is focused on early-stage biotech and healthcare investments. He currently serves on the Board of Directors of EpiBiologics, Juvena Therapeutics, Light Horse Therapeutics, and as a Board Observer at Dewpoint Therapeutics and Auron Therapeutics. Prior to his current position, Dr. Hannoush spent fifteen years at Genentech where he was a Senior Group Leader, and he led both early- and late-stage discovery biology programs in Ophthalmology, Immunology and Oncology, with a focus on drug discovery and development, as well as target discovery and validation. His Laboratory in translational biology at Genentech focused on new drug modalities and understanding the role of protein – protein interactions in stem cell signaling pathways for cellular reprogramming and tissue regeneration, and his group made important contributions in the fields of Wnt signaling and protein lipidation. He obtained his PhD in Chemistry from McGill University and did his postdoctoral training in chemical biology and cell biology at Harvard. He is also currently an adjunct Professor at the Department of Chemical and Systems Biology at Stanford.